Quixabeira, D. C. A. http://orcid.org/0000-0003-2614-3942
Pakola, S. http://orcid.org/0000-0001-6235-8612
Jirovec, E.
Havunen, R.
Basnet, S.
Santos, J. M.
Kudling, T. V. http://orcid.org/0000-0003-4481-1617
Clubb, J. H. A.
Haybout, L.
Arias, V.
Grönberg-Vähä-Koskela, S.
Cervera-Carrascon, V.
Kerkelä, E. http://orcid.org/0000-0002-2923-5300
Pasanen, A. http://orcid.org/0000-0002-0079-9807
Anttila, M. http://orcid.org/0000-0003-4089-1357
Tapper, J.
Kanerva, A.
Hemminki, A. http://orcid.org/0000-0001-7103-8530
Article History
Received: 13 April 2023
Revised: 31 August 2023
Accepted: 29 September 2023
First Online: 10 November 2023
Competing interests
: AH is a shareholder in Targovax ASA. AH, JMS, and VCC are employees and shareholders in TILT Biotherapeutics. DQ, RH, and JC are employees of TILT Biotherapeutics.
: Usage of human OvCa specimens was approved prior collection by the Central Hospital Operative Ethics Committee (Helsinki, Finland) under the permit number 120/13/03/02/16. Sample collection was conditioned to patient´s signing of written informed consent, and researchers had no access to any of the patients´ personal information. Animal work was approved by the Experimental Animal Experimental Board (ELLA) of the University of Helsinki and the Provincial Government of Southern Finland (license number ESAVI/12559/2021) and were performed in accordance with FELASA guidelines.
: Not applicable.